Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: A placebo-controlled randomized study

BJU International

Volumn 89, Issue 6, 2002, Pages 583-590

  Torring N ^a   Moller Ernst Jensen K ^a   Lund, L ^a   Nielsen, J E ^a   Djurhuus, J C ^a   Poulsen, S S ^b   Nexo E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amphiregulin; Betacellulin; BPH; EGF; Finasteride; HER1; HER2; Prostate; TGF

Indexed keywords

AMPHIREGULIN; BETACELLULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FINASTERIDE; GROWTH FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; RECEPTOR SUBTYPE; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE SECRETION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL; SECRETORY CELL; STROMA CELL; TISSUE LEVEL;

EPIDERMAL GROWTH FACTOR; FINASTERIDE; GLYCOPROTEINS; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0036346366     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.02665.x     Document Type: Article

References (35)

1. Etiology of benign prostatic hyperplasia
2. The development of human benign prostatic hyperplasia with age
3. Etiology and disease process of benign prostatic hyperplasia
4. Characterization and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic hyperplasia and prostatic carcinoma
5. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia
6. Evidence for atrophy and apoptosis in the prostates of men given finasteride
7. Proscar: Five-year experience
8. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension study
9. Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia
10. The proliferative function of basal cells in the normal and hyperplastic human prostate
11. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture
12. The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates
13. Chronic treatment with epidermal growth factor (EGF) induces growth of the rat ventral prostate
14. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities
15. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
16. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates
17. A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: Evaluation, interpretations and limitations
18. Human epidermal growth factor - On molecular forms present in urine and blood
19. An immunoassay designed to quantitate different molecular forms of rat urinary epidermal growth factor with equimolar potency: Application on fresh rat urine
20. Adsorption of EGF receptor ligands to test tubes - A factor with implications for studies on the potency of these peptides
21. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines
22. Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia
23. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates
24. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma
25. Developmental and hormonal regulation of transforming growth factor-alpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells
26. Amphiregulin is expressed in primary cultures of prostate myofibroblasts, fibroblasts, epithelial cells, and in prostate tissue
27. Epidermal growth factor receptor-dependent stimulation of amphiregulin expression in androgen-stimulated human prostate cancer cells
28. Epidermal growth factor in the rat prostate. Production, tissue content and molecular forms in the different prostatic lobes
29. Growth factors in the prostate
30. Immunohistochemical localization of epidermal growth factor and transforming growth factor alpha in the male rat accessory sex organs
31. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy
32. Role of submandibular saliva and epidermal growth factor in gastric cytoprotection
33. Amphiregulin is coordinately expressed with heparin-binding epidermal growth factor-like growth factor in the interstitial smooth muscle of the human prostate
34. Heparin-binding EGF-like growth factor expression increases selectively in bladder smooth muscle in response to lower urinary tract obstruction
35. Systemic treatment with epidermal growth factor but not insulin-like growth factor I decreases the involution of the prostate in castrated rats